Avidity Biosciences, Inc. — Director's Dealing 2024

Jun 15, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2024-06-12

Reporting Person: LEVIN ARTHUR A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-12	Common Stock	S	40000	$35.0657	Disposed	213872	Indirect
2024-06-13	Common Stock	S	60000	$40.0797	Disposed	153872	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-13	Stock Option (Right to Buy)	$39.96	A	13489	Acquired	2034-06-12	Common Stock (13489)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	14830	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on May 26, 2023 by the Reporting Person.

F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.89. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.